Medtronic (MDT) Stock Forecast & Price Target

Medtronic logo
$100.36 -0.25 (-0.24%)
As of 03:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
8
Buy
18

Based on 27 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 1 has given a sell rating, 8 have given a hold rating, and 18 have given a buy rating for MDT.

Consensus Price Target

$104.17
3.79% Upside
According to the 27 analysts' twelve-month price targets for Medtronic, the average price target is $104.17. The highest price target for MDT is $120.00, while the lowest price target for MDT is $83.00. The average price target represents a forecasted upside of 3.79% from the current price of $100.36.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDT Analyst Ratings Over Time

TypeCurrent Forecast
11/20/25 to 11/20/26
1 Month Ago
10/21/25 to 10/21/26
3 Months Ago
8/22/25 to 8/22/26
1 Year Ago
11/20/24 to 11/20/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
18 Buy rating(s)
18 Buy rating(s)
18 Buy rating(s)
13 Buy rating(s)
Hold
8 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
12 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$104.17$102.88$98.83$109.61
Forecasted Upside3.79% Upside10.57% Upside5.77% Upside10.31% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medtronic Stock vs. The Competition

TypeMedtronicHealthcare CompaniesBroader Market
Consensus Rating Score
2.63
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside1.65% Upside117.37% Upside19.14% Upside
News Sentiment Rating
Positive News

See Recent MDT News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/19/2026
BTIG Research logo
BTIG Research
3 of 5 stars
Ryan Zimmerman
Ryan Zimmerman
3 of 5 stars
Boost TargetBuy$99.00 ➝ $109.00+8.18%
11/17/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Joshua Jennings
3 of 5 stars
Set TargetBuy$110.00+6.97%
11/17/2026
Piper Sandler logo
Piper Sandler
2 of 5 stars
Matt O'Brien
Matt O'Brien
2 of 5 stars
UpgradeNeutral ➝ Overweight$85.00 ➝ $120.00+16.59%
10/19/2026 UpgradeHold (C+) ➝ Buy (B-)
10/14/2026Reiterated RatingCautious
10/7/2026UpgradeHold
9/17/2026Reiterated RatingBuy
9/3/2026 Reiterated RatingHold$92.00-0.04%
9/2/2026Set Target$115.00+24.86%
9/2/2026Boost TargetBuy$95.00 ➝ $110.00+19.67%
URGENT: If you own a home, please review the map below. (Ad)

More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel

See the map and get the full details on what this means for you
9/2/2026Boost TargetOverweight$102.00 ➝ $104.00+13.14%
9/2/2026Reiterated RatingHold$86.00 ➝ $99.00+7.70%
9/2/2026Reiterated RatingOutperform$118.00+28.37%
9/2/2026Boost TargetNeutral$91.00 ➝ $100.00+8.79%
9/2/2026Boost TargetHold$80.00 ➝ $95.00+3.35%
7/6/2026Set Target$105.00+27.49%
6/5/2026 Lower TargetBuy$111.00 ➝ $106.00+28.58%
6/4/2026Lower TargetOutperform$112.00 ➝ $97.00+17.46%
6/4/2026Reiterated RatingHold$88.00+12.70%
6/4/2026 Lower TargetNeutral$100.00 ➝ $86.00+4.07%
6/4/2026Lower TargetNeutral$84.00 ➝ $83.00+0.55%
6/4/2026Lower TargetOutperform$117.00 ➝ $104.00+33.19%
4/7/2026Lower TargetBuy$117.00 ➝ $110.00+27.75%
4/6/2026Lower TargetBuy$125.00 ➝ $115.00+32.76%
2/27/2026 Lower TargetBuy$117.00 ➝ $115.00+17.83%
1/30/2026 Initiated CoverageOutperform
1/6/2026UpgradeMarket Perform ➝ Outperform
11/19/2025Boost TargetOverweight$107.00 ➝ $117.00+16.20%
6/30/2025UpgradeUnderperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:11 PM ET.


Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 18, 2026. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Medtronic plc:

  • Medtronic plc recently secured FDA clearance for its Hugo robotic-assisted surgery system for general surgery, a significant regulatory milestone that expands the addressable market for the company's surgical portfolio and positions it to compete more broadly in the rapidly growing surgical robotics sector.
  • The company demonstrated strong fundamental performance in its most recent quarterly report, beating analyst consensus estimates with earnings per share of $1.45 against an expected $1.39 and generating revenue of $9.76 billion, which reflects a 13.7% year-over-year increase and signals robust demand for its medical technologies.
  • Medtronic plc offers a compelling income opportunity with a current dividend yield of 2.81%, providing investors with a steady stream of cash flow that is attractive for income-focused portfolios seeking stability in the healthcare sector.
  • With a current stock price of $100.76, the shares are trading below the consensus price target of $102.88, suggesting potential for capital appreciation as analysts maintain a Moderate Buy rating based on the company's growth prospects in cardiovascular and neuroscience segments.
  • The company is expanding its vascular portfolio through the planned $380 million acquisition of Contego Medical, a move that enhances its capabilities in treating carotid artery disease and peripheral thrombectomy, thereby strengthening its competitive position in the cardiovascular market.

Medtronic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Medtronic plc for these reasons:

  • Recent insider activity indicates potential lack of confidence or profit-taking, as CEO Geoffrey Martha and EVP Michael Marinaro both sold significant blocks of shares in October 2026, with the CEO reducing his ownership stake by 15.25% in a single transaction.
  • Wall Street Zen recently downgraded Medtronic plc from a buy to a hold rating, signaling that some analysts believe the stock's current valuation may not fully reflect its future growth potential or that there are emerging risks in the company's outlook.
  • The company faces margin and currency headwinds that could pressure profitability, as noted in recent analyst commentary, which may limit the upside for earnings growth despite strong revenue performance in key segments.
  • Short interest in Medtronic plc shares increased significantly in the most recent reporting period, with shares shorted rising to 139,004,337, indicating that a substantial portion of the market is betting against the stock's price appreciation.
  • Medtronic plc has a high dividend payout ratio of 70.94%, which means the company is distributing a large portion of its earnings to shareholders, potentially limiting its ability to reinvest in research and development or acquisitions to drive long-term growth.

MDT Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $104.17, with a high forecast of $120.00 and a low forecast of $83.00.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 3.79% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 4 upgrades by analysts.

Analysts like Medtronic more than other "healthcare" companies. The consensus rating for Medtronic is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MDT compares to other companies.


MarketBeat monitors more than a dozen sources for Medtronic analyst ratings, with the most recent rating issued on 11/19/2026.
From Our Partners